Premium
Methionine synthase 2756AA polymorphism is associated with the risk of cognitive impairment in patients with late‐life depression
Author(s) -
Yang YaHsu,
Chiu ChihChiang,
Teng HaoWei,
Chu ChihPang,
Chang ChingJui,
Chiu WeiChe,
Chen ChinHsin,
Lu MongLiang,
Liu ShenIng,
Huang ShihYi,
Liu HsingCheng,
Sun IWen
Publication year - 2017
Publication title -
asia‐pacific psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.654
H-Index - 21
eISSN - 1758-5872
pISSN - 1758-5864
DOI - 10.1111/appy.12242
Subject(s) - methylenetetrahydrofolate reductase , homocysteine , methionine synthase , genotype , apolipoprotein e , medicine , odds ratio , allele , cognitive impairment , depression (economics) , polymorphism (computer science) , confidence interval , genetics , psychology , methionine , gastroenterology , cognition , psychiatry , biology , gene , disease , macroeconomics , amino acid , economics
Backgrounds Apolipoprotein E epsilon‐4 (APOE ε4) allele, methylenetetrahydrofolate reductase (MTHFR C677T), and methionine synthase (MTR A2756G) were tested their associations with cognitive impairment in people with late‐life depression (LLD). Methods People with LLD were assessed by mini‐mental state examination and were examined the distribution of APOE ε4 allele, MTHFR, and MTR polymorphisms. Results Odds ratio of MTR 2756 AA to MTR 2756 AG and GG genotypes for the risk of cognitive impairment was 5.80 (95% confidence interval = 1.18–28.50; P = 0.03). Conclusion People with LLD carrying MTR2756 AA genotype have higher risk of cognitive impairment than those carrying G allele.